Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 3;14(4):1003-1012.
doi: 10.1080/21645515.2017.1409316. Epub 2017 Dec 21.

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

Yang Wang  1 , Jingxin Li  2 , Yuxiao Wang  1 , Wei Gu  3 , Fengcai Zhu  2
Affiliations
Review

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

Yang Wang et al. Hum Vaccin Immunother. .

Abstract

Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people ≥ 2 years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults.

Keywords: clinical trials; high-risk population; immunization strategy; pneumococcal polysaccharide vaccine; vaccine efficacy.

PubMed Disclaimer

References

    1. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007;7(9):597–606. doi: 10.1016/S1473-3099(07)70210-4. PMID:17714673. - DOI - PubMed
    1. Calix JJ, Porambo RJ, Brady AM, Larson TR, Yother J, Abeygunwardana C, Nahm MH. Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae Serotype 20 strains: discovery of a new pneumococcal sertype. J Biol Chem. 2012;287(33):27885–27894. doi: 10.1074/jbc.M112.380451. PMID:22736767. - DOI - PMC - PubMed
    1. Aliberti S, Mantero M, Mirsaeidi M, Blasi F. The role of vaccination in preventing pneumococcal disease in adults. Clin Microbiol Infect. 2014;20(Supplement s5):52–58. doi: 10.111/1469-0691.12518. PMID:24410778. - DOI - PMC - PubMed
    1. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760. doi: 10.1016/S1473-3099(11)70090-1. PMID:21621466. - DOI - PubMed
    1. Horácio AN, Diamantino-Miranda J, Aguiar SI, Ramirez M, Melo-Cristino J, Portuguese group for study of streptococcal infections. Serotype changes in adult invasive pneumococcal infections in Portugal did not reduce the high fraction of potentially vaccine preventable infections. Vaccine. 2012;30(2):218–224. PMID:22100892. doi: 10.1016/j.vaccine.2011.11.022 - DOI - PubMed

MeSH terms

Substances